+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Idiopathic Constipation Therapeutic Market by Product Type, Route of Administration, Distribution Channel, Treatment Type - Global Forecast to 2030- Product Image
Chronic Idiopathic Constipation Therapeutic Market by Product Type, Route of Administration, Distribution Channel, Treatment Type - Global Forecast to 2030- Product Image
Sale

Chronic Idiopathic Constipation Therapeutic Market by Product Type, Route of Administration, Distribution Channel, Treatment Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010861
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Idiopathic Constipation Therapeutic Market grew from USD 619.07 million in 2024 to USD 670.23 million in 2025. It is expected to continue growing at a CAGR of 8.11%, reaching USD 988.78 million by 2030.

Setting the Stage for Chronic Idiopathic Constipation Solutions

Chronic idiopathic constipation represents a critical condition affecting millions of individuals worldwide, challenging clinicians and pharmaceutical developers alike. This summary opens the door to a deeper understanding of the factors that drive therapeutic innovation and patient outcomes in this often-overlooked disorder. By tracing the evolution of treatment options from bulk-forming agents to advanced prokinetic therapies, the foundation is laid for appreciating the nuanced interplay among efficacy, safety, and patient adherence. Furthermore, this introduction contextualizes the current landscape against a backdrop of shifting regulatory frameworks and evolving patient expectations, setting the scene for the comprehensive insights that follow.

In the pages ahead, you will discover how market forces, clinical breakthroughs, and policy adjustments converge to shape the trajectory of product portfolios. With a focus on both established categories and next-generation modalities, this executive summary highlights the strategic imperatives that stakeholders must address to maintain competitiveness. By framing the discussion around patient-centric outcomes and sustainable value creation, the narrative emphasizes the long-term potential that lies at the intersection of clinical need and commercial opportunity.

Revolutionizing the Chronic Constipation Treatment Paradigm

The chronic constipation treatment arena has witnessed transformative shifts driven by advances in mechanism of action and patient-centric design. Emerging osmotic formulations leverage novel excipients to improve water retention with greater tolerability, while designer stimulants target enteric neurons with precision to reduce cramping. Concurrently, the maturation of biologic therapies and microbiome-modulating approaches is redefining the therapeutic paradigm by addressing underlying pathophysiology rather than solely inducing laxation.

In addition to pharmaceutical innovation, the integration of digital health platforms and telemedicine has reconfigured patient engagement. Real-time symptom tracking and adherence reminders facilitate proactive management, enabling clinicians to tailor regimens based on individual response patterns. This convergence of digital tools with advanced therapeutics underscores a shift from episodic treatment to continuous care, fostering improved long-term outcomes. As stakeholders adapt to these dynamics, strategic investment in integrated solutions and evidence generation will determine the next wave of market leadership.

Implications of Upcoming US Tariff Adjustments in 2025

Looking ahead to 2025, scheduled adjustments in United States tariffs on active pharmaceutical ingredients and excipients are poised to reshape cost structures across the supply chain. Manufacturers sourcing bulk-forming polymers or osmotic agents may encounter recalibrated import duties that alter raw material economics. In turn, these shifts could influence pricing strategies for both branded and generic products, potentially compressing margins or necessitating portfolio realignment.

Moreover, contract manufacturers and ingredient suppliers are preparing to mitigate tariff-related disruptions by diversifying sourcing footprints. Some are exploring partnerships with domestic producers, while others are investing in nearshore options to streamline logistics and limit exposure. As the tariff landscape evolves, agile procurement strategies and transparent cost modeling will be essential to sustaining profitability without compromising product accessibility.

Unveiling Deep-Dive Segmentation Perspectives

A granular examination of therapeutic segments reveals distinct drivers and competitive dynamics. In bulk-forming laxatives, methylcellulose, polycarbophil, and psyllium husk each carve unique value propositions through differences in fiber viscosity, swell ratio, and tolerability, while lubricant formulations appeal to patients seeking minimal water intake requirements. Osmotic categories span lactulose, polyethylene glycol, saline solutions, and sugar alcohols, with each excipient offering differentiated onset of action and side effect profiles. Similarly, stimulant agents such as bisacodyl and senna remain staples for rapid relief, though their positioning must balance efficacy against concerns over long-term dependence.

Route of administration further stratifies market potential, as capsule, liquid suspension, syrup, enema, and suppository formats cater to diverse patient preferences and adherence considerations. Capsules and tablets dominate convenience-oriented regimens, whereas rectal applications fill critical niches in acute care settings. Distribution channels shape accessibility: hospital pharmacies ensure supply for inpatient protocols, retail outlets offer over-the-counter ease, and online pharmacies provide discrete home delivery. Treatment type delineates regulatory pathways and marketing approaches, with over-the-counter availability driving volume through self-care channels while prescription products rely on clinician engagement and reimbursement frameworks in clinics and hospitals.

Regional Dynamics Shaping Treatment Trajectories

Regional landscapes present a tapestry of opportunities and challenges that inform market entry and expansion strategies. In the Americas, the United States leads with a sophisticated reimbursement environment and strong emphasis on value-based contracting, whereas key Latin American markets continue to prioritize generic accessibility amid budgetary pressures. In Europe, Middle East & Africa, stakeholders must navigate a mosaic of regulatory standards, reimbursement models, and healthcare infrastructure, with Western Europe exhibiting advanced patient-access programs and emerging economies in Eastern Europe and the Middle East focusing on cost containment.

Asia-Pacific embodies both high-growth potential and complexity, as mature markets such as Japan and Australia drive innovation adoption while populous nations like China and India pursue local production of bulk-forming agents and stimulate generic competition. Within each region, evolving healthcare policies, demographic trends, and consumer behaviors converge to define unique strategic imperatives. Forward-looking organizations will align product development and market access plans with region-specific priorities, leveraging partnerships and tailored value propositions to optimize penetration and sustain growth.

Competitive Landscape and Leading Innovators Overview

A competitive review highlights the diverse array of players shaping the chronic constipation therapeutics market. Established pharmaceutical companies with expansive R&D pipelines are driving next-generation osmotic and prokinetic agents through late-stage trials, while specialty biotech firms are advancing novel peptide and microbiome-based candidates. Concurrently, generic manufacturers maintain price leadership in traditional laxative segments, leveraging scale and streamlined operations to capture volume-driven markets. Contract development and manufacturing organizations are also integral, providing formulation expertise and capacity to support both branded and generic portfolios.

Strategic partnerships and licensing deals are increasingly common as companies seek to accelerate time-to-market and broaden geographical reach. Collaborative agreements between innovators and local distributors enable rapid market entry, while joint ventures concentrated on emerging economies facilitate tailored manufacturing solutions. Patents expiring for pivotal prokinetic therapies have opened the door for biosimilars and authorized generics, intensifying competition and compelling originators to differentiate through enhanced formulations and value-added services.

Strategic Imperatives for Industry Front-Runners

Industry leaders must adopt a multi-pronged approach to secure sustainable advantage in this dynamic environment. First, prioritizing innovation in formulation science will differentiate products through improved tolerability, targeted delivery, and patient-centric design. Second, integrating real-world evidence and digital health assets into clinical programs will provide compelling data to support value-based contracting and payer negotiation. Third, supply chain resilience should be buttressed by diversified sourcing strategies and agile manufacturing frameworks that can respond swiftly to tariff shifts and regulatory changes.

Furthermore, cultivating strategic alliances with regional distributors and healthcare providers will enhance market access and foster advocacy among key opinion leaders. Investing in educational initiatives for both clinicians and patients can accelerate adoption of new modalities, while patient support programs reinforce adherence and reinforce brand loyalty. Finally, scenario-based planning that anticipates shifts in reimbursement landscapes and competitive moves will empower decision-makers to adapt resource allocation and pricing tactics proactively, ensuring agility in the face of uncertainty.

Robust Methodology Underpinning Our Insights

The underlying research methodology blends rigorous analysis of secondary sources, expert interviews, and cross-validation techniques to yield robust and unbiased insights. Initially, publicly available literature, regulatory filings, and clinical trial registries were systematically reviewed to capture the latest efficacy and safety profiles of existing and emerging therapies. This foundation was supplemented by in-depth discussions with leading gastroenterologists, pharmacologists, and health economists to contextualize clinical data within real-world practice dynamics.

To ensure comprehensive coverage, a triangulation framework was employed, reconciling discrepancies across data sources and quantifying qualitative findings through structured scoring models. Geographic segmentation was informed by an overlay of regional regulatory guidelines, reimbursement policies, and distribution infrastructures. Lastly, peer review by independent analysts validated key conclusions and reinforced methodological integrity, delivering actionable insights grounded in transparent and repeatable processes.

Converging Insights Towards a Unified Outlook

In synthesizing these findings, it becomes evident that the chronic idiopathic constipation market is at an inflection point. Clinical advancements, shifting policy levers, and evolving patient expectations converge to create both complexity and opportunity. Stakeholders who align their strategies with deep segmentation insights, regional nuances, and competitive imperatives will be better positioned to capture value and drive meaningful patient outcomes.

As the competitive landscape intensifies, the ability to anticipate change, innovate responsibly, and collaborate effectively will distinguish the next generation of market leaders. Ultimately, a holistic approach that unites scientific rigor with commercial acumen will unlock the full potential of chronic constipation therapeutics and set a new benchmark for patient-centric care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Bulk-Forming Laxatives
      • Methylcellulose
      • Polycarbophil
      • Psyllium Husk
    • Lubricant Laxatives
    • Osmotic Laxatives
      • Lactulose
      • Peg
      • Saline Laxatives
      • Sugar Alcohols
    • Stimulant Laxatives
      • Bisacodyl
      • Senna
    • Stool Softeners
  • Route Of Administration
    • Oral
      • Capsule
      • Liquid Formulations
        • Suspension
        • Syrup
      • Tablet
    • Rectal
      • Enema
      • Suppository
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Treatment Type
    • Over-The-Counter
      • Online Pharmacies
      • Retail Pharmacies
    • Prescription
      • Clinics
      • Hospital Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Allergan plc
  • Ironwood Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt plc
  • Synergy Pharmaceuticals, Inc.
  • Almirall, S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Idiopathic Constipation Therapeutic Market, by Product Type
8.1. Introduction
8.2. Bulk-Forming Laxatives
8.2.1. Methylcellulose
8.2.2. Polycarbophil
8.2.3. Psyllium Husk
8.3. Lubricant Laxatives
8.4. Osmotic Laxatives
8.4.1. Lactulose
8.4.2. Peg
8.4.3. Saline Laxatives
8.4.4. Sugar Alcohols
8.5. Stimulant Laxatives
8.5.1. Bisacodyl
8.5.2. Senna
8.6. Stool Softeners
9. Chronic Idiopathic Constipation Therapeutic Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsule
9.2.2. Liquid Formulations
9.2.2.1. Suspension
9.2.2.2. Syrup
9.2.3. Tablet
9.3. Rectal
9.3.1. Enema
9.3.2. Suppository
10. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Chronic Idiopathic Constipation Therapeutic Market, by Treatment Type
11.1. Introduction
11.2. Over-The-Counter
11.2.1. Online Pharmacies
11.2.2. Retail Pharmacies
11.3. Prescription
11.3.1. Clinics
11.3.2. Hospital Pharmacies
12. Americas Chronic Idiopathic Constipation Therapeutic Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Chronic Idiopathic Constipation Therapeutic Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Allergan plc
15.3.2. Ironwood Pharmaceuticals, Inc.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. Mallinckrodt plc
15.3.5. Synergy Pharmaceuticals, Inc.
15.3.6. Almirall, S.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PSYLLIUM HUSK, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LUBRICANT LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PEG, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SALINE LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUGAR ALCOHOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BISACODYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SENNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ENEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SUPPOSITORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 78. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 79. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 80. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 82. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 83. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 84. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 87. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 96. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 149. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 157. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 160. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 161. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 163. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 164. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 165. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 168. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 169. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 172. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 185. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 187. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 188. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 189. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 191. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 192. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 193. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 196. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 197. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 199. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 200. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 201. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 203. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 204. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 205. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 208. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 245. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 247. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 248. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 251. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 253. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TABLE 256. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING LAXATIVES, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC LAXATIVES, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STIMULANT LAXATIVES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OVER-THE-COUNTER, 2018-2030 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Idiopathic Constipation Therapeutic market report include:
  • Allergan plc
  • Ironwood Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt plc
  • Synergy Pharmaceuticals, Inc.
  • Almirall, S.A.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 670.23 Million
Forecasted Market Value ( USD ) by 2030 $ 988.78 Million
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Constipation Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Constipation Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Constipation Treatment - Global Strategic Business Report - Product Image

Constipation Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Constipation Treatment Market Report 2025 - Product Image

Constipation Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast to 2030 - Product Image

Opioid Induced Constipation Market by Product Type, Oral, Rectal - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Opioid-Induced Constipation Treatment Market Report 2025 - Product Image

Opioid-Induced Constipation Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Chronic Idiopathic Constipation Drugs Market

Within the realm of gastrointestinal drugs, a distinct segment is dedicated to the treatment of Chronic Idiopathic Constipation (CIC), a prevalent condition characterized by infrequent bowel movements, difficulty in stool passage, or a sense of incomplete evacuation without an identifiable cause. The market for CIC medications includes a range of therapeutic options that aim to alleviate symptoms and improve patients' quality of life. These pharmacologic treatments largely consist of laxatives, stool softeners, prokinetic agents, chloride channel activators, guanylate cyclase-C agonists, and serotonin 5-HT4 receptor agonists, each targeting different aspects of the complex gastrointestinal function to induce bowel movements or enhance stool consistency. Development in this sector is driven by a combination of factors, including advancing understanding of gut motility and the nervous system, patient need, and innovation in drug design and delivery mechanisms. Several companies have established prominence in the Chronic Idiopathic Constipation Drugs market through the development and commercialization of effective treatments. Leading this niche are pharmaceutical firms such as Ironwood Pharmaceuticals, Takeda Pharmaceutical Company, Synergy Pharmaceuticals, Ardelyx, Pfizer, and Allergan. These companies offer a diverse portfolio of products and continue to invest in research and development to improve therapeutic outcomes and address unmet medical needs within the discipline of gastrointestinal health. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.